Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Breast cancer
Closed
Phase 2
This study is looking at adding tucatinib to trastuzumab and capecitabine for people whose advanced breast cancer has continued to grow despite treatment.
It is for people whose breast cancer is . This means the breast cancer cells have tested positive for a protein called HER2.
Recruitment start: 1 July 2017
Recruitment end: 3 May 2019
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Andrew Wardley
Seattle Genetics Inc
Last reviewed: 30 May 2019
CRUK internal database number: 15262
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
